Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: OKG-0301 for Acute Adenoviral Conjunctivitis
NCT03856645Phase 2Unknown
- Sponsor
- Okogen
- Start
- Feb 2019
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ranpirnase in acute adenoviral conjunctivitis, sponsored by Okogen. Status: unknown.
02
Drugs
ranpirnase
03
Conditions
acute adenoviral conjunctivitis
Beyond the preview
Go deeper on NCT03856645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856645.